Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 2/2014

01.02.2014 | R&D Insight Report

Ibrutinib: First Global Approval

verfasst von: Fiona Cameron, Mark Sanford

Erschienen in: Drugs | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Ibrutinib (Imbruvica™) is a small molecule, first-in-class, once-daily, orally available, Bruton’s tyrosine kinase inhibitor that is under development for the treatment of B cell malignancies, including chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL), as well as multiple myeloma (MM), follicular lymphoma (FL) and Waldenstrom’s macroglobulinemia (WM). It has been developed by Pharmacyclics, Inc. and Janssen Biotech, Inc. Ibrutinib acts by blocking B-cell antigen receptor signalling, thereby reducing malignant proliferation of B cells and inducing cell death. Based chiefly on findings from a phase Ib/II study, ibrutinib has been approved in the USA for the treatment of MCL in previously treated patients and is one of the first approvals through the US FDA’s Breakthrough Therapy Designation Pathway. An application has been filed in the EU seeking regulatory approval in this indication. In both the USA and EU, further applications have been filed with regulatory bodies seeking approval for the use of ibrutinib in patients with previously treated CLL/small lymphocytic lymphoma (SLL). Phase III trials are underway worldwide to evaluate ibrutinib in the treatment of patients with CLL/SLL, DLBCL and MCL, and the agent is in phase II development for use in WM, FL and MM. This article summarizes the milestones in the development of ibrutinib leading to its first approval in MCL.
Literatur
1.
2.
Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1922–2001. Blood. 2006;107(1):265–76.PubMedCrossRef
3.
4.
Murawski N, Pfreundschuh M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol. 2010;11(11):1074–85.PubMedCrossRef
5.
Chang JE, Kahl BS. Current status of targeted therapies for mantle cell lymphoma. Drugs. 2011;71:2307–26.PubMedCrossRef
6.
Danilov AV. Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther. 2013;35(9):1258–70.PubMedCrossRef
7.
Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: the Bruton’s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013;31(1):128–30.PubMedCrossRef
8.
9.
Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94.PubMedCrossRef
10.
11.
12.
13.
14.
15.
16.
Pharmacyclics, Inc. Pharmacyclics announces collaboration with the National Cancer Institute to develop its novel Btk Inhibitor, PCI-32765 in hematologic malignancies [media release]. Aug 9 2011. http://​www.​pharmacyclics.​com.
17.
18.
Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–49.PubMedCrossRef
19.
Honigberg LA, Smith AM, Loury DJ. A clinical trial of the Bruton’s tyrosine kinase inhibitor PCl-32765 in naturally occurring canine lymphoma [abstract no. 3740]. In: 100th Annual Meeting of the American Association for Cancer Research; Apr 18–22 2009; Denver.
20.
Honigberg L, Smith A, Chen J, et al. PCL-31523: an irreversible inhibitor of Bruton’s tyrosine kinase that disrupts B cell receptor signaling, is cytotoxic to B cell lymphomas, and is active in an animal arthritis model [abstract no. 5398]. In: 98th Annual Meeting of the American Association for Cancer Research; Apr 14–18 2007; Los Angeles.
21.
Ponader S, Chen SS, Buggy JJ, et al. Bruton’s tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182–9.PubMedCrossRef
22.
23.
Elias L, Chen J, Buggy J. BTK inhibitor ibrutinib inhibits breast cancer growth by inhibiting ErbB2 kinase [abstract no. C258]. In: 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Oct 19–23 2013, Boston.
24.
Lobe CG, Allain MJ, Yang W. Activity of BTK and HDAC inhibitors alone and in combination in a mouse model of non-small cell lung cancer [abstract no. C243]. In: 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Oct 19–23 2013, Boston.
25.
Vij R, Chang BY, Berdeja JG, et al. Early changes in cytokines, chemokines and indices of bone metabolism in a phase 2 study of the Bruton tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765) in patients with relapsed or relapsed/refractory multiple myeloma (MM) [abstract no. 653]. In: 54th Annual Meeting of the American Society of Hematology; Dec 8–11 2012, Atlanta.
26.
Nathan F, Jeff S, Sonali S, et al. A phase I trial of BTK inhibitor PCI-32765 in patients with relapsed non-Hodgkin’s lymphoma: evidence of antitumor activity [abstract no. 0893]. In: 15th Congress of the European Haematology Association; Jun 10–13 2010, Barcelona.
27.
Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.PubMedCrossRef
28.
Wiestner A, Farooqui M, Valdez J, et al. Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukaemia patients with 17p deletion. Hematol Oncol. 2013;31:98.
29.
Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.PubMedCentralPubMed
30.
Brown JR, Barrientos JC, Barr PM, et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a phase 1b study [abstract no. 525]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7–10 2013; New Orleans.
31.
Burger JA, Keating MJ, Wierda WG, et al. Efficacy and safety of ibrutinib in combination with rituximab in high-risk CLL patients. Hematol Oncol. 2013;31:193–4.
32.
Burger JA, Keating MJ, Wierda WG, et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induced a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a phase II trial in 40 patients [abstract no. 675]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7–10 2013; New Orleans.
33.
Farooqui M, Aue G, Valdez J, et al. Single agent ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p [abstract no. 673]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7–10 2013; New Orleans.
34.
O’Brien S, Furman RR, Fowler N, et al. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) monotherapy demonstrates long-term safety and durability of response in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients in an open-label extension study [abstract no. 4163]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7–10 2013; New Orleans.
35.
Wilson WH, Gerecitano JF, Goy A, et al. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study [abstract no. 686]. In: 54th Annual Meeting of the American Society of Hematology; Dec 8–11 2012, Atlanta.
36.
deVos S, Wilson WH, Gerecitano JF, et al. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed/refractory (RR) DLBCL: interim phase 2 results [abstract no. S1180]. In: 18th Congress of the European Haematology Association; Jun 13–16 2013, Stockholm.
37.
Treon S, Tripsas C, Yang G, et al. A prospective, multicentre, phase II study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed and refractory Waldenstrom’s macroglobulinemia [abstract no. 067]. Hematol Oncol. 2013;31:119.CrossRef
38.
Treon SP, Tripsas K, Yang G, et al. A prospective multicenter study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom’s macroglobulimemia [abstract no. 251]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7–10 2013, New Orleans.
39.
Abbott, Inc. Abbott to collaborate with Janssen and Pharmacyclics on development of companion test for investigational leukemia therapy [media release]. Feb 21 2013. http://​www.​abbott.​com.
40.
Metadaten
Titel
Ibrutinib: First Global Approval
verfasst von
Fiona Cameron
Mark Sanford
Publikationsdatum
01.02.2014
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 2/2014
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0178-8

Weitere Artikel der Ausgabe 2/2014

Drugs 2/2014 Zur Ausgabe

Leading Article

Does Treatment of Psoriasis Reduce the Risk of Cardiovascular Disease?

Adis Drug Evaluation

Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer

Review Article

Acute Hyperglycemia Associated with Short-Term Use of Atypical Antipsychotic Medications

Adis Drug Evaluation

Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection

R&D Insight Report

Sofosbuvir: First Global Approval

Adis Drug Evaluation

Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus